Thus, the direct comparison of major covariates ( Supplementary Table S5 ) demonstrated that almost all of them showed highly significant differences between the historical data set and the blinatumomab trial.
← all excerpts
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
1
—
—